Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.35 |
| ▸ | TUBB | P07437 | 4/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.35 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.35 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.35 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.35 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.35 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.35 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.35 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.35 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.35 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.35 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.35 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.35 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.34 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4641977 | 0.90 | ENPP2 (0.38) | ENPP2CA1CA2TUBB1TUBB4A | |
| SCHEMBL10165239 | 0.88 | ENPP2 (0.36) | ENPP2CA1CA2TUBB1TUBB4A | |
| SCHEMBL21048124 | 0.86 | ENPP2 (0.40) | ENPP2CA1CA2LMNARAB9A | |
| SCHEMBL29490924 | 0.83 | HTR2A (0.35) | ENPP2CA1CA2 | |
| SCHEMBL16654543 | 0.83 | HTR2A (0.35) | ENPP2CA1CA2 | |
| SCHEMBL7435094 | 0.79 | CYP3A4 (0.42) | ENPP2CA1CA2TUBB1TUBB4A | |
| SCHEMBL4671676 | 0.79 | ENPP2 (0.43) | ENPP2CA1CA2TUBB1TUBB4A | |
| SCHEMBL3327791 | 0.79 | CA1 (0.48) | ENPP2CA1CA2CYP3A4MAPT | |
| SCHEMBL24433 | 0.79 | CYP3A4 (0.56) | ENPP2CA1CA2TUBB1TUBB4A | |
| SCHEMBL4109993 | 0.77 | ENPP2 (0.41) | ENPP2CA1CA2TUBB1TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020247160-A1 | CONDENSED TRYCICLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED. | 2020-11-19 | — | — | US | disclosed |
| US-10668067-B2 | Pyridine sulfonamides | AMGEN INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190167682-A1 | PYRIDINE SULFONAMIDES | AMGEN INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-7196101-B2 | Bis(5-aryl-2-pyridyl) compound having excellent immunoglobulin (IgE) antibody production inhibiting activity, useful for the prevention or treatment of allergic immune diseases | KOWA CO., LTD (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20050101634-A1 | Bis(5-aeyl-2-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| US-6890940-B2 | Bis(2-aryl-5-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2005-05-10 | — | — | US | disclosed |
| US-6706703-B2 | BIS(5-ARYL-2-PYRIDYL) COMPOUND HAVING EXCELLENT IMMUNOGLOBULIN (IGE) ANTIBODY PRODUCTION INHIBITING ACTIVITY, USEFUL FOR THE PREVENTION OR TREATMENT OF ALLERGIC IMMUNE DISEASES | KOWA CO., LTD. (JP) | 2004-03-16 | — | — | US | disclosed |
| US-20030027814-A1 | Bis(5-aryl-2-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2003-02-06 | — | — | US | disclosed |
| US-20030022886-A1 | Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy | KOWA CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101634-A1 | Bis(5-aeyl-2-pyridyl) derivatives | H1-0, BRD4, PAH | ENPP2 1436/4885CA1 2904/4885CA2 422/4885 |
| US-20030022886-A1 | Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy | IGLV6-57, IL5, IGSF11 | ENPP2 460/4885CA1 4674/4885CA2 2579/4885 |
| US-20030027814-A1 | Bis(5-aryl-2-pyridyl) derivatives | AHR, PAH, H1-0 | ENPP2 2995/4885CA1 4598/4885CA2 2662/4885 |
| US-20190167682-A1 | PYRIDINE SULFONAMIDES | TRPV1, TRPA1, TRPV5 | ENPP2 490/4885CA1 2445/4885CA2 355/4885 |
| US-10668067-B2 | Pyridine sulfonamides | TRPV1, TRPA1, TRPV5 | ENPP2 490/4885CA1 2445/4885CA2 355/4885 |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINA3 | ENPP2 1809/4885CA1 2768/4885CA2 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.